Zacks Research Has Weak Outlook for Henry Schein Q1 Earnings

Henry Schein, Inc. (NASDAQ:HSIC) – Zacks Research dropped their Q1 2026 EPS estimates for Henry Schein in a report released on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.20 per share for the quarter, down from their previous forecast of $1.22. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q3 2026 earnings at $1.43 EPS, Q4 2026 earnings at $1.44 EPS, FY2026 earnings at $5.26 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.62 EPS, FY2027 earnings at $5.76 EPS and FY2028 earnings at $6.28 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

Other research analysts have also recently issued research reports about the company. Barclays began coverage on Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Barrington Research set a $97.00 price objective on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. JPMorgan Chase & Co. upped their target price on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a report on Monday, March 9th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $72.24 on Thursday. The company has a market cap of $8.29 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 2.15 and a beta of 0.88. Henry Schein has a 52 week low of $60.56 and a 52 week high of $89.29. The business has a 50 day moving average price of $77.72 and a 200-day moving average price of $72.98. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the transaction, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. This represents a 1.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 105,911 shares of company stock valued at $8,574,982 in the last ninety days. 1.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC bought a new position in Henry Schein during the second quarter valued at about $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein in the fourth quarter worth about $30,000. Federated Hermes Inc. purchased a new position in Henry Schein in the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC purchased a new position in Henry Schein in the fourth quarter valued at about $37,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate to $1.62 from $1.44, signaling stronger expected back‑half performance for FY2027. Zacks note
• Positive Sentiment: Zacks boosted its Q3 2027 EPS to $1.49 from $1.42 and lifted FY2027 to $5.76 from $5.68, implying improved full‑year outlook beyond FY2026. Zacks note
• Positive Sentiment: Zacks nudged FY2026 guidance upward to $5.26 from $5.23 and raised Q3 2026 to $1.43 (from $1.39) and Q4 2026 to $1.44 (from $1.43), reflecting incremental improvement to near‑term full‑year estimates. Zacks note
• Neutral Sentiment: Zacks published an FY2028 EPS projection of $6.28 (new/forward‑looking estimate). This provides a growth runway but is not a direct revision to consensus today. Zacks note
• Negative Sentiment: Zacks cut its Q2 2027 EPS forecast to $1.38 from $1.47, a notable downgrade for the mid‑year quarter that may pressure near‑term expectations. Zacks note
• Negative Sentiment: Zacks trimmed Q1 2027 to $1.28 from $1.35 and lowered Q1 2026 to $1.20 from $1.22, indicating weaker near‑term quarterly visibility. Zacks note

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.